MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly
March 14 2019 - 9:00AM
MannKind Corporation (Nasdaq:MNKD) announced today
it is sponsoring Conor Daly as he makes his debut with the Andretti
Autosport team at the 103rd Running of the Indianapolis 500 on May
26, 2019. MannKind is an associate sponsor of Andretti Autosport
for this race and will partner with Daly on his No. 25 U.S. Air
Force Honda. Daly was diagnosed with Type 1 diabetes at the age of
14, and now lends his racing career to raise awareness of diabetes
treatment options and innovations.
“Living with diabetes since age 14 has been a
challenge, but one that I’ve always faced head on,” said
Daly. “Managing my diabetes properly has been a key to being
able to live my racing dream. Diabetes should never stop
you from pursuing what you want in life! Thanks to
MannKind I will be able to share my story and live my dream at a
higher level than ever."
“MannKind is continually seeking platforms to
increase awareness around the challenges, opportunities and
successes people living with diabetes encounter on a daily basis,”
says Michael Castagna, CEO of MannKind. “Seeing someone like
Conor take on a challenging sport such as IndyCar racing, while
having to manage his diabetes, is an inspiration to all those
living with diabetes. We are excited to be associated with Conor
and Andretti Autosport for the Indy 500 and look forward to a
partnership where we can help educate people on treatment options
for managing their diabetes.”
As an associate sponsor of Daly at the Indy 500,
MannKind is planning events and experiences that build awareness of
innovation in diabetes treatment. The events and sponsorship
promotion will also allow for Daly to share his story about living
with diabetes.
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only inhaled
rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing and
research facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
About Andretti AutosportLed by
racing legend Michael Andretti, Andretti Autosport boasts a wide
racing portfolio rooted in tradition and designed for success.
Under the banners of Andretti Autosport,
Andretti Rallycross and Andretti Formula E, the Indianapolis-based
team fields multiple entries across the IndyCar Series, Indy
Lights, the FIA Formula E Championship, the GT4 America Series and
Americas Rallycross. Additionally, the team competes as Walkinshaw
Andretti United in the Australian Supercars category through
partnership with Walkinshaw Racing and United Autosports.
The global racing enterprise boasts four IndyCar
Series championships, three Indy Lights titles, one Pro Mazda
championship and one USF2000 championship, and has captured victory
five times at the famed Indianapolis 500-Mile Race. Additionally,
the team holds two X Games Gold Medals and four U.S. rallycross
championships.
To share in the Andretti story, please visit
online at AndrettiAutosport.com and follow along on social media
with #AllAndretti.
Company Contact: Rose Alinaya SVP, Investor
Relations 818-661-5000 ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024